SCHEMBL16440960

SCHEMBL16440960

CON(C)C(=O)c1ccc2c(c1)CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
SLC6A3 Q01959 1/20 0.47
OPRM1 P35372 1/20 0.45
OPRD1 P41143 1/20 0.45
RXRB P28702 3/20 0.45
RXRA P19793 2/20 0.45
RXRG P48443 2/20 0.45
MLYCD O95822 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 8/20 0.43
RAB9A P51151 8/20 0.43
MAPT P10636 2/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TRPC6 Q9Y210 1/20 0.42
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8256846 0.83 ALDH1A1 (0.61) ALDH1A1OPRM1OPRD1RXRBRXRA
SCHEMBL30386375 0.83 MLYCD (0.43) ALDH1A1SLC6A3OPRM1OPRD1MLYCD
SCHEMBL25259720 0.83 MLYCD (0.43) ALDH1A1SLC6A3OPRM1OPRD1MLYCD
SCHEMBL14898447 0.81 MAOA (0.45) MLYCD
SCHEMBL14101096 0.81 MELK (0.45)
SCHEMBL28737571 0.80 ALDH1A1 (0.56) ALDH1A1RXRBRXRARXRGMEN1
SCHEMBL29521402 0.79 SLC6A3 (0.38) ALDH1A1SLC6A3OPRM1OPRD1RXRB
SCHEMBL4224828 0.78 HDAC6 (0.46) ALDH1A1MEN1KMT2ANPC1
SCHEMBL20812222 0.77 ALDH1A1 (0.54) ALDH1A1OPRM1OPRD1RXRBRXRA
SCHEMBL883530 0.76 ALDH1A1 (0.61) ALDH1A1MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP ALDH1A1 3792/4885SLC6A3 3405/4885OPRM1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.